By subtly threatening the loss of patients via a new "reference lab network," the Indianapolis-based health insurer has persuaded 63 Indiana hospitals to slash their prices for blood and tissue testing by as much as 80 percent—beyond the discounts Anthem had already negotiated with them.
The fact that Assembly Biosciences Inc. and AgeneBio now list New York and Baltimore, respectively, as their headquarters cities doesn’t hurt Indiana and could help the state, says David Johnson, CEO of BioCrossroads.
Indiana’s health care companies attracted $103.8 million in investments last year, the highest total since attracting 2007. However, all but $3 million of last year’s investments came during the first six months of the year and Indiana continued to lag other Midwest states.
The CEOs of Anthem, Lilly, Zimmer and Hill-Rom tried to woo investors at the J.P. Morgan Healthcare conference by stressing how they're broadening business beyond plain-old insurance, pharmaceuticals, implants and hospital beds.